ClinicalTrials.gg
RecruitingNCT03214354Sickle-AIDUpdated May 1, 2026

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

A Phase 2 interventional study of Alemtuzumab and Total Body Irradiation in Sickle Cell Disease, Stem Cell Transplant Complications and Red Blood Cell Disorder, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 1 Year to 19 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Calgary · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
1 Year to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing alemtuzumab in Anemia, Sickle Cell — 6 open to participants now, 14 under way, none of them phase 3. Alemtuzumab · Anemia, Sickle Cell.

Planned enrollment
16th of 22
12 · median 44
Started
2017
with 2 others
Phase 2
11 of 22
4 open now
Primary completion
2028-07
later than 8 of 13 live
Registered
14th of 22
by date

Among the 22 studies testing alemtuzumab in Anemia, Sickle Cell, this one is the 16th largest by planned enrollment, is one of 3 that started in 2017, is one of 11 in phase 2, reaches primary completion later than 8 of the 13 other live ones, and was the 14th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

6 of the 22 studies testing alemtuzumab in Anemia, Sickle Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About alemtuzumab

Alemtuzumab: first FDA approval 2001 (LEMTRADA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing alemtuzumab in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.

Read the detailed description

Sickle cell disease (SCD) is a debilitating chronic blood disorder with multi-system end-organ damage that leads to morbidity and early mortality. The only cure for SCD is hematopoietic stem cell transplantation (HSCT), which given the risks with unrelated HSCT, is only an option for a minority of patients who have a matched sibling donor.

In the field of HSCT, blood group ABO incompatibility between donor and recipient is not a contraindication and several studies do not show compromised outcomes. However, in the context of nonmyeloablative (NMA) conditioning and major ABO-incompatibility, when the recipient has existing antibodies to donor red blood cells, pure red cell aplasia (PRCA) may occur.

This phase II pilot study will enroll SCD patients with a matched related major ABO-incompatible donor to determine the safety and efficacy of NMA-HSCT. Biological studies will include a plan to study and monitor red cell engraftment in this population to facilitate early detection and interventional measures to prevent and treat PRCA.

03

Conditions studied

  • Sickle Cell Disease
  • Stem Cell Transplant Complications
  • Red Blood Cell Disorder
  • Pure Red Cell Aplasia

Keywords

  • sickle cell disease
  • stem cell transplant
  • red blood cell engraftment
  • nonmyeloablative
  • pure red cell aplasia
04

Who can participate

Ages eligible
1 Year to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 12 months and \< 19 years of age at the time of study enrollment.
  • Patients must have sickle cell disease as defined by electropheresis, as follows:

    • homozygous Hb S disease (HbSS),
    • sickle-Hb C disease (HbSC),
    • sickle beta-plus-thalassemia (HbS/β+), or
    • sickle beta-null-thalassemia (HbS/βo)
  • Patients must meet standard eligibility criteria to undergo , including but not limited to one or more of the following:

    • history of repeated (more than 1) bony (vaso-occlusive) crisis
    • history of stroke
    • elevated transcranial Doppler velocity not eligible for hydroxyurea, as per TWiTCH trial (ie. severe vasculopathy)
    • history of acute chest crisis or splenic sequestration crisis
    • history of priapism in males
    • history of osteonecrosis
    • pulmonary hypertension as documented by tricuspid regurgitation jet velocity (TRV) > 2.5 m/s on echocardiogram
    • red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy
  • Sickle complications should be present despite the use of hydroxyurea, but this is not an absolute requirement, if the treating team considers the patient to be at high risk for further crisis episodes.

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to comply with or follow the study protocol.
  • Patients with known to sirolimus, its derivatives or to any of its components.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Non-myeloablative conditioning

    Non-myeloablative conditioning

    Drug: Alemtuzumab · Radiation: Total Body Irradiation · Drug: Sirolimus

Interventions

  • Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days

    Also known as: Campath

  • RadiationTotal Body Irradiation

    TBI 300 cGy on Day -2

    Also known as: TBI

  • Sirolimus is used for GVHD prophylaxis

06

What researchers measure

Primary outcomes

  1. Incidence of pure red cell aplasia (PRCA)

    Clinical definition: reticulocytopenia \< 10x109/L (\< 1%) lasting more than 60 days after HSCT, or Pathological definition: the absence of erythroid precursors in the marrow in the setting of adequate myeloid, lymphoid and megakaryocytic precursors

    Time frame: 6 months from enrollment

Secondary outcomes

  1. RBC chimerism measured by peripheral blood flow cytometry

    Peripheral blood for RBC chimerism on flow sorted erythroid precursor cells

    Time frame: 12 months

  2. RBC chimerism measured by bone marrow BFU-erythroid forming colonies

    Bone marrow will be performed between Day +45 and +60

    Time frame: 2 months

  3. Primary graft failure

    Measured by donor chimerism from peripheral blood and bone marrow

    Time frame: 6 weeks

  4. Secondary graft failure

    Measured by donor chimerism in peripheral blood and bone marrow

    Time frame: 24 months

  5. Disease recurrence

    Measured by peripheral blood Hb S level

    Time frame: 24 months

  6. Incidence and severity of acute GVHD

    Acute GVHD grade will be accessed using modified CIBMTR criteria

    Time frame: 100 days

  7. Incidence and severity of chronic GVHD

    Chronic GVHD will be accessed using the NIH consensus criteria

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
    Recruiting
    • Tony Truong, MD, MPH · Contacttony.truong@ahs.ca · 403-955-7272
    • Greg Guilcher, MD · Contact403-955-7272
    • Tony Truong, MD, MPH · Principal investigator
    • Greg Guilcher, MD · Sub investigator
    • Victor Lewis, MD · Sub investigator
    • Michael Leaker, MD · Sub investigator
    • Aisha Bruce, MD · Sub investigator
    • Aru Narendran, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Jul 2028, 132 months after the start.

Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 132 months is above that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2017
First posted
Jul 11, 2017
StartActual
Jul 5, 2017
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03214354
Responsible party
Tony H. Truong (Pediatric Hematologist/Oncologist, University of Calgary) — Principal investigator
First posted
Jul 11, 2017
Start date
Jul 5, 2017
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
May 1, 2026

Study contacts

Tony Truong, MD, MPH
Contact
tony.truong@ahs.ca
403-955-7272
Greg Guilcher, MD
Contact
403-955-7272

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alemtuzumab · Sirolimus

Start the discussion